文献速递肺结节与肺癌

按EBUS-TBNA诊断的N分期评估非小细胞肺癌长期生存

Long-term Survival According to N Stage Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Non-small Cell Lung Cancer.
PubMed 文献 · Chest · 2021-12-08

该回顾性研究纳入1089例接受EBUS-TBNA初始分期的非小细胞肺癌患者,按EBUS-TBNA诊断的临床N分期(eN分期)分析5年生存。eN0-1、eN2、eN3的5年总生存率分别为57.4%、23.2%、12.8%,各期差异显著。假阴性EBUS-TBNA病例的5年生存率与pN1患者相近。

要点

  • EBUS-TBNA诊断的eN分期与NSCLC长期生存显著相关。
  • eN0-1、eN2、eN3的5年总生存率分别为57.4%、23.2%、12.8%。
  • 假阴性EBUS-TBNA病例生存与pN1相似,支持阴性后手术。

核心结论

  • NSCLC患者按EBUS-TBNA诊断的eN分期不同,长期生存存在显著差异,凸显EBUS-TBNA在NSCLC分期中的重要性。
  • 假阴性EBUS-TBNA病例的生存率与pN1患者相似,可能为EBUS-TBNA阴性后行手术提供依据。

研究设计与样本

  • 回顾性研究,纳入2006年1月至2011年12月期间接受EBUS-TBNA(±经食管途径)进行初始分期的NSCLC患者1089例。
  • EBUS-TBNA阴性病例未行纵隔镜检查。
  • 按eN分期和治疗方式行5年生存分析,并将假阴性EBUS-TBNA病例与同期941例非EBUS-TBNA的pN0-1患者比较生存。

主要发现

  • 1089例患者中eN0-1组681例、eN2组314例、eN3组94例;eN0-1与eN2生存差异P<.0001,eN2与eN3差异P=.0118。
  • 估计5年总生存率:eN0-1为57.4%,eN2为23.2%,eN3为12.8%。
  • eN0-1和eN2患者中,手术病例生存均优于非手术病例(eN0-1手术vs非手术P<.0001;eN2手术vs非手术P<.0001)。
  • eN0-1患者中假阴性55例(eN0-1/pN2-3,其中pN2 54例、pN3 1例)。
  • pN0、pN1和eN0-1/pN2-3的5年总生存率分别为76.4%、56.0%和56.4%;eN0-1/pN2-3生存劣于pN0(P=.0061),与pN1无显著差异(P=.9191)。

临床怎么用

  • EBUS-TBNA诊断的eN分期可用于NSCLC预后分层。
  • EBUS-TBNA阴性结果后行手术可能是合理的,因假阴性病例生存与pN1相似。

局限性

  • 回顾性研究设计。
  • EBUS-TBNA阴性病例未行纵隔镜检查,可能存在假阴性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the main procedure for mediastinal staging. However, long-term survival analyses according to clinical nodal stage diagnosed by EBUS-TBNA (eN stage) have not been reported. The value of EBUS-TBNA has not been assessed through an analysis of survival in false-negative EBUS-TBNA cases. RESEARCH QUESTION: What is the prognostic impact of eN stage in non-small cell lung cancer (NSCLC)? What is the survival rate in false-negative EBUS-TBNA cases? STUDY DESIGN AND METHODS: We retrospectively (January 2006 to December 2011) reviewed the medical records of patients with NSCLC who underwent EBUS-TBNA (± transesophageal approach) for initial staging (N = 1,089). Mediastinoscopy was not performed for EBUS-TBNA-negative cases. We performed 5-year survival analyses according to eN stage and treatment modality. Survival in false-negative EBUS-TBNA cases was compared with that in patients with pN0-1, including 941 non-EBUS-TBNA cases, during the same period. RESULTS: Among the 1,089 patients undergoing EBUS-TBNA (eN0-1: n = 681; eN2: n = 314; eN3: n = 94), we observed significant differences in survival between the eN stages (eN0-1 vs eN2: P < .0001; eN2 vs eN3: P = .0118; estimated 5-year overall survival [5YOS] rate: eN0-1 = 57.4%, eN2 = 23.2%, eN3 = 12.8%). Surgery cases had better survival than nonsurgery cases among patients with eN0-1 and eN2 (eN0-1/surgery vs eN0-1/no surgery: P < .0001; eN2/surgery vs eN2/no surgery: P < .0001). Among the patients with eN0-1, there were 55 false-negative cases (eN0-1/pN2-3, pN2: n = 54; pN3: n = 1). The 5YOS rates of patients with pN0, pN1, and eN0-1/pN2-3 were 76.4%, 56.0%, and 56.4%, respectively. Patients with eN0-1/pN2-3 had worse survival than patients with pN0 (P = .0061), whereas there was no significant difference compared with patients with pN1 (P = .9191). INTERPRETATION: Long-term survival significantly differed according to eN stage in NSCLC, highlighting the importance of EBUS-TBNA in NSCLC staging. False-negative EBUS-TBNA cases had favorable survival which was similar to that of patients with pN1, which may provide a rationale for performing surgery after negative EBUS-TBNA results.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Hwangbo B, Park EY, Yang B, et al. Long-term Survival According to N Stage Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Non-small Cell Lung Cancer. Chest. 2021. PMID: 34896095. doi:10.1016/j.chest.2021.11.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。